tiprankstipranks
Atea Pharmaceuticals announces upcoming presentations at ICAR
The Fly

Atea Pharmaceuticals announces upcoming presentations at ICAR

Atea Pharmaceuticals announced six upcoming presentations at the 36th International Conference on Antiviral Research, ICAR, which will take place March 13-17, 2023 in Lyon, France. Presentation details are as follows: Title: The Combination of Bemnifosbuvir and Ruzasvir, the HCV NS5B and NS5A Inhibitors, Demonstrates Potent In Vitro Synergistic Antiviral Activity and In Vivo Preclinical Safety Without Adverse Interactions. Title: Low Risk of Drug-Drug Interactions for Bemnifosbuvir Based Upon In Vitro Metabolism and Transporter Interaction Studies. Title: Pharmacokinetics and Metabolism of [14C]-Bemnifosbuvir in Healthy Male Participants. Title: Bemnifosbuvir a Potent Inhibitor of SARS-CoV-2 Variants of Concern, and a Promising Oral Antiviral with a High Resistance Barrier for Treatment of COVID-19 and other Coronaviruses Infections. Title: AT-752 Targets Multiple Sites and Activities on the Dengue Virus Replication Enzyme NS5. Title: Five Cellular Enzymes in the Activation Pathway of Bemnifosbuvir, a Drug-Candidate Against SARS-CoV-2 Infections.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on AVIR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles